BioNexus Gene Lab (BGLC) Cash & Equivalents (2018 - 2026)

BioNexus Gene Lab's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 35.98% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 35.98% YoY), while the FY2025 annual figure was $2.4 million, down 17.44% from the prior year.
• Cash & Equivalents came in at $1.3 million for Q1 2026 at BioNexus Gene Lab, down from $2.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $6.1 million in Q3 2023 to a low of $1.2 million in Q3 2025.
• A 5-year average of $2.5 million and a median of $2.1 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 320.37% in 2023 and slumped 61.2% in 2025, its largest moves.
• BioNexus Gene Lab's Cash & Equivalents stood at $2.1 million in 2022, then jumped by 113.21% to $4.5 million in 2023, then tumbled by 36.1% to $2.9 million in 2024, then decreased by 17.44% to $2.4 million in 2025, then tumbled by 43.88% to $1.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.3 million, $2.4 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison